Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway

Oncogene volume 43, pages 388–394 (2024)Cite this article

Subjects

Abstract

Tumor immune evasion is a hallmark of Head and Neck Cancers. The advent of immune checkpoint inhibitors (ICIs) in the first-line setting has transformed the management of these tumors. Unfortunately, the response rate of Head and Neck Squamous Cell Carcinomas (HNSCC) to ICIs is below 15%, regardless of the human papillomavirus (HPV) status, which might be partially related with impaired antigen presentation machinery (APM). Mechanistically, HNSCC cells are usually defective in the expression of MHC-I associated APM, while this transcriptional pathway is critical for the activation of tumor-killing effector T-cells. To specifically illuminate the phenomenon and seek for therapeutic strategies, this review summarizes the most recently identified role of genetic and functional dysregulation of the MHC-I pathway, specifically through changes at the genetic, epigenetic, post-transcriptional, and post-translational levels, which substantially contributes to HNSCC immune escape and ICI resistance. Several treatment modalities can be potentially exploited to restore APM signaling in tumors, which improves anti-tumor immunity through the activation of interferons, vaccines or rimantadine against HPV and the inhibition of EGFR, SHP-2, PI3K and MEK. Additionally, the combinatorial use of radiotherapy or cytotoxic agents with ICIs can synergize to potentiate APM signaling. Future directions would include further dissection of MHC-I related APM signaling in HNSCC and whether reversing this inhibition in combination with ICIs would elicit a more robust immune response leading to improved response rates in HNSCC.

Therapeutic approaches to restore the MHC-I antigen presentation machinery in Head and Neck Cancer. (Red color texts represent the according strategies and the outcomes).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic image illuminating the physiological MHC-I antigen presentation of altered proteins from tumor cell to cytotoxic T cell mediated by several pivotal APM proteins and MHC-I complex.
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.

    Article  PubMed  Google Scholar 

  2. Menezes F, Fernandes GA, Antunes J, Villa LL, Toporcov TN. Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: a systematic review of population-based studies. Oral Oncol. 2021;115:105177.

    Article  PubMed  Google Scholar 

  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  PubMed  Google Scholar 

  4. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC Class I antigen presentation. Front Immunol. 2021;12:636568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.

    Article  CAS  PubMed  Google Scholar 

  7. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl J Med. 2018;378:1976–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Eggermont A, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643–54.

    Article  CAS  PubMed  Google Scholar 

  9. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611:155–60.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  10. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl J Med. 2016;375:1856–67.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Greene S, Patel P, Allen CT. How patients with an intact immune system develop head and neck cancer. Oral Oncol. 2019;92:26–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol. 2016;58:52–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tan YS, Sansanaphongpricha K, Prince M, Sun D, Wolf GT, Lei YL. Engineering vaccines to reprogram immunity against head and neck cancer. J Dent Res. 2018;97:627–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005;11:2552–60.

    Article  CAS  PubMed  Google Scholar 

  16. Koene G, Mulder A, van der Ven K, Eijsink C, Franke M, Slootweg P, et al. Human monoclonal antibodies as a tool for the detection of HLA class I allele-specific expression loss in head-and-neck squamous cell carcinoma and corresponding lymph node metastases. Hum Immunol. 2006;67:692–9.

    Article  CAS  PubMed  Google Scholar 

  17. Bandoh N, Ogino T, Katayama A, Takahara M, Katada A, Hayashi T, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep. 2010;23:933–9.

    Article  CAS  PubMed  Google Scholar 

  18. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res. 2005;93:189–234.

    Article  CAS  PubMed  Google Scholar 

  19. López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402–9.

    Article  PubMed  Google Scholar 

  20. Sant A, Yewdell J. Antigen processing and recognition. Curr Opin Immunol. 2003;15:66–8.

    Article  CAS  PubMed  Google Scholar 

  21. Rammensee HG, Falk K, Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 1993;11:213–44.

    Article  CAS  PubMed  Google Scholar 

  22. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol. 2002;3:1177–84.

    Article  CAS  PubMed  Google Scholar 

  23. Reeves E, Wood O, Ottensmeier CH, King EV, Thomas GJ, Elliott T, et al. HPV epitope processing differences correlate with ERAP1 Allotype and Extent of CD8(+) T-cell Tumor Infiltration in OPSCC. Cancer Immunol Res. 2019;7:1202–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Investig. 2006;116:3006–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hafstrand I, Sayitoglu EC, Apavaloaei A, Josey BJ, Sun R, Han X, et al. Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin. Proc Natl Acad Sci USA. 2019;116:5055–60.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  26. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890–5.

    Article  CAS  PubMed  Google Scholar 

  27. Kelly A, Trowsdale J. Genetics of antigen processing and presentation. Immunogenetics. 2019;71:161–70.

    Article  CAS  PubMed  Google Scholar 

  28. Jongsma M, Guarda G, Spaapen RM. The regulatory network behind MHC class I expression. Mol Immunol. 2019;113:16–21.

    Article  CAS  PubMed  Google Scholar 

  29. Zhou F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol. 2009;28:239–60.

    Article  CAS  PubMed  Google Scholar 

  30. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA. 1998;95:15623–8.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  31. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Investig. 2018;128:3813–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bhat FA, Mohan SV, Patil S, Advani J, Bhat MY, Patel K, et al. Proteomic alterations associated with oral cancer patients with tobacco using habits. OMICS. 2021;25:255–68.

    Article  CAS  PubMed  Google Scholar 

  33. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006;66:9281–9.

    Article  CAS  PubMed  Google Scholar 

  34. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19:306–27.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Cillo AR, Kürten C, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52:183–99. e9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wuerdemann N, GĂĽltekin SE, PĂĽtz K, Wittekindt C, Huebbers CU, Sharma SJ, et al. PD-L1 expression and a high tumor infiltrate of CD8+ lymphocytes predict outcome in patients with oropharyngeal squamous cells carcinoma. Int J Mol Sci. 2020;21:5228.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Saloura V, Fatima A, Zewde M, Kiyotani K, Brisson R, Park JH, et al. Characterization of the T-Cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and Neck. Clin Cancer Res. 2017;23:4897–907.

    Article  CAS  PubMed  Google Scholar 

  38. Miyauchi S, Kim SS, Jones RN, Zhang L, Guram K, Sharma S, et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 2023;42:112508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, et al. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Investig. 2020;130:1635–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den Tweel J, et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens. 1999;54:235–45.

    Article  CAS  PubMed  Google Scholar 

  41. Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother. 2002;51:389–96.

    Article  CAS  PubMed  Google Scholar 

  42. Vougiouklakis T, Bao R, Nakamura Y, Saloura V. Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck. Oncotarget. 2017;8:112797–808.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Nigam N, Bernard B, Sevilla S, Kim S, Dar MS, Tsai D, et al. SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. Cell Rep. 2023;42:112823.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents Anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020;26:290–300.

    Article  CAS  PubMed  Google Scholar 

  45. Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol. 2020;13:25.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20:835–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Li H, Xiong HG, Xiao Y, Yang QC, Yang SC, Tang HC, et al. Long non-coding RNA LINC02195 as a regulator of MHC I molecules and favorable prognostic marker for head and neck squamous cell carcinoma. Front Oncol. 2020;10:615.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Gao F, Zhao ZL, Zhao WT, Fan QR, Wang SC, Li J, et al. miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2013;431:610–6.

    Article  CAS  PubMed  Google Scholar 

  49. Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, et al. HPV16 E5 Mediates Resistance to PD-L1 Blockade and can be targeted with rimantadine in head and neck cancer. Cancer Res. 2020;80:732–46.

    Article  CAS  PubMed  Google Scholar 

  50. Gameiro SF, Zhang A, Ghasemi F, Barrett JW, Nichols AC, Mymryk JS. Analysis of Class I major histocompatibility complex gene transcription in human tumors caused by human papillomavirus infection. Viruses. 2017;9:252.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005;65:11146–55.

    Article  CAS  PubMed  Google Scholar 

  53. Vambutas A, DeVoti J, Pinn W, Steinberg BM, Bonagura VR. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol. 2001;101:94–9.

    Article  CAS  PubMed  Google Scholar 

  54. Li W, Deng XM, Wang CX, Zhang X, Zheng GX, Zhang J, et al. Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression. Int J Gynecol Cancer. 2010;20:227–32.

    Article  PubMed  Google Scholar 

  55. Zhang J, Tan GL, Jiang M, Wang TS, Liu GH, Xiong SS, et al. Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma. Cell Signal. 2023;101:110530.

    Article  CAS  PubMed  Google Scholar 

  56. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother. 2011;60:525–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy. Cell. 2016;167:397–404. e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 2020;10:1140–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Chandrasekaran S, Sasaki M, Scharer CD, Kissick HT, Patterson DG, Magliocca KR, et al. Phosphoinositide 3-Kinase signaling can modulate MHC Class I and II expression. Mol Cancer Res. 2019;17:2395–409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023;41:304–22. e7.

    Article  CAS  PubMed  Google Scholar 

  61. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signaling prevents anti-tumour immunity. Nature. 2015;523:231–5.

    Article  CAS  PubMed  ADS  Google Scholar 

  62. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Gong W, Donnelly CR, Heath BR, Bellile E, Donnelly LA, Taner HF, et al. Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion. Oncoimmunology. 2021;10:1997385.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol. 2022;23:1379–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, et al. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res. 2013;19:798–808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst. 2014;106:dju215.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Kang SH, Keam B, Ahn YO, Park HR, Kim M, Kim TM, et al. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. Oncoimmunology. 2019;8:e1515057.

    Article  PubMed  Google Scholar 

  68. Takahashi H, Kawabata-Iwakawa R, Ida S, Mito I, Tada H, Chikamatsu K. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma. Sci Rep. 2021;11:17789.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  69. Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16:1260–70.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  70. Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, et al. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. Clin Cancer Res. 2018;24:4242–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Heath BR, Gong W, Taner HF, Broses L, Okuyama K, Cheng W, et al. Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. Cell Rep. 2023;42:112303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, et al. STAT1-Induced HLA Class I upregulation enhances immunogenicity and clinical response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res. 2015;3:936–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kao HF, Liao BC, Huang YL, Huang HC, Chen CN, Chen TC, et al. Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clin Cancer Res. 2022;28:1560–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Wang HC, Chan LP, Cho SF. Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Front Oncol. 2019;9:1084.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, et al. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res. 2017;5:1141–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank all authors of these original studies who conducted these relevant researches referenced in this review. This work is supported by National Natural Science Foundation of China (82272899, 81902782 are awarded to XL, 81730030 is awarded to QC, 82203180 is awarded to YQ), Research Funding from West China School/Hospital of Stomatology Sichuan University (No.RCDWJS2022-16, to XL), the 14th special grant from China Postdoctoral Science Foundation (2021T140484, to XL), Postdoctoral Research Funding of Sichuan University (2022SCU12132, to XL), Research and Exploration Program of West China Hospital of Stomatology of Sichuan University(No. RD-02-202204, to XL), Key Research Program of Sichuan Provincial Science and Technology Agency (2023YFS0127, to XL) and the CAMS Innovation Fund for Medical Sciences(CIFMS,2019-I2M-5-004, to QC).

Author information

Author notes

  1. These authors contributed equally: Xiaobo Luo, Yan Qiu.

Authors and Affiliations

  1. State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Research Unit of Oral Carcinogenesis and Management & Chinese Academy of Medical Sciences, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, China

    Xiaobo Luo, Qiuhao Wang & Qianming Chen

  2. Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China

    Yan Qiu

  3. Department of Periodontics and Oral Medicine, Department of Otolaryngology–Head and Neck Surgery, Rogel Cancer Center, the University of Michigan, Ann Arbor, MI, 48109, USA

    Zackary R. Fitzsimonds & Yu Leo Lei

Authors
  1. Xiaobo Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zackary R. Fitzsimonds
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiuhao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qianming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Leo Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XL and YQ contributed to the conception, design, drafting and revision of the manuscript; YLL and QC contributed to the conception, review, and revision of the manuscript; ZRF, QW contributed to the revision and figure production of the manuscript; All authors read and approved the final manuscript. XL and YQ made equal contributions as co-first authors.

Corresponding authors

Correspondence to Qianming Chen or Yu Leo Lei.

Ethics declarations

Competing interests

YLL co-founded and serves on the Scientific Advisory Board of Saros Therapeutics. All other authors declare no conflicts of interest with relevance to this article. No medical writer or generative AI tool was involved in the preparation of the manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, X., Qiu, Y., Fitzsimonds, Z.R. et al. Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway. Oncogene 43, 388–394 (2024). https://doi.org/10.1038/s41388-023-02912-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-023-02912-2

Search

Advanced search

Quick links